A research study to evaluate the safety and effectiveness of an investigational drug is currently being conducted in adults with moderate to severe ulcerative colitis. The aim of the international study is to evaluate the efficacy and safety of Infliximab in patients with active ulcerative colitis. The study is being conducted in the US, Canada, Denmark, Spain, UK, Belgium and Germany.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Have had ulcerative colitis of at least 3 months duration.
• Have active disease
• Are at least 18 years old.
• Agree to use a barrier method of birth control during the study.

Exclusion Criteria

Patients will not be eligible for this study if they:

• Have severe colitis
• Are pregnant or breast-feeding.
• Have used investigational drug within 30 days prior to screening.
• Have received previous administration of infliximab.
• Have a concomitant diagnosis of congestive heart failure (CHF).